All Type 2 diabetes articles
-
NewsNICE launches consultation on updated type 2 diabetes guidance
The consultation period closes on 14 October 2021, and publication of the final guideline is expected on 15 February 2022
-
Independent professional body guideline
ABCD position on cardiovascular impact of glucose-lowering drugs
Key recommendations from the ABCD position statement on new glucose-lowering drugs concerning their cardiovascular impact on people with diabetes
-
News
People seeking weight loss help are heavier than those pre-pandemic, study finds
The study highlights the need for people to take action on unhealthy weight gain to safeguard against the increased risk of developing type 2 diabetes
-
Working party guideline/algorithm
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.
-
News
NICE publishes an update to guidance on chronic kidney disease
Updated NICE guideline covers investigation and treatment of chronic kidney disease and associated disorders
-
Independent professional body guideline
BSPID gum disease and diabetes guideline
A short overview of periodontal (gum disease) and its links with diabetes, including advice for community pharmacy teams
-
Independent professional body guideline
Type 2 diabetes pharmacological management pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN
-
Independent professional body guideline
CaReMeUK cardiovascular risk optimisation algorithm
A guide for non-diabetes specialist physicians and primary care teams for cardiovascular risk optimisation in patients with type 2 diabetes and atherosclerotic cardiovascular disease
-
Supplement
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103452 Date of preparation: January 2021 -
Supplement
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines for Nurses.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103453 Date of preparation: January 2021 -
NICE guideline
NICE diabetes in pregnancy guideline
An up-to-date summary of NICE guidance on diabetes management in pregnancy. Includes gestational diabetes, preconception, antenatal, and postnatal care.
-
NICE guideline
NICE type 2 diabetes in children guideline
This succinct Guidelines summary advises on the appropriate diagnosis and management of type 2 diabetes mellitus in children and young people.
-
NICE guideline
NICE type 2 diabetes guideline
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management
-
Independent professional body guideline
KDIGO guideline on diabetes management in CKD
Recommendations on comprehensive care, glycaemic monitoring and targets, lifestyle and antihyperglycaemic interventions, and approaches to self-management and optimal models of care
-
NHS guideline
NHS guideline for delivering diabetes care during COVID-19
This NHS guidance for general practice covers the key points of delivering diabetes care during the challenging times of the COVID-19 pandemic
-
News
New clinical guideline released for managing diabetes in chronic kidney disease
KDIGO has published a new clinical guideline for diabetes management in chronic kidney disease that includes comprehensive care, glycemic monitoring and targets, lifestyle and antihyperglycemic interventions
-
Independent professional body guideline
PCDE pharmacological management of type 2 diabetes
This succinct summary highlights the treatment recommendations for type 2 diabetes by cardiovascular/renal disease or risk factor.
-
Video
Dr David Unwin Q&A on type 2 diabetes
In this video, taken at Guidelines Live 2019, Dr David Unwin answers questions on dietary management of diabetes and offers his key take-home messages.
-
Video
Michelle Lam Q&A on type 2 diabetes
In this video, taken at Guidelines Live 2019, Michelle Lam answers questions about guidance on managing type 2 diabetes, the differences between the guidelines, and her key take-home messages.
-
Working party guideline/algorithm
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.
![20210603 Guidelines comparison table [online]](https://d3j7puhwqgd8ts.cloudfront.net/Pictures/100x67//0/0/0/10000_20210603guidelinescomparisontableonline_766677.png)
